Clinical Trials Logo

Clinical Trial Summary

This parallel, randomized, open-label study will evaluate the effect on overall survival of irinotecan on oxaliplatin and 5-fluorouracil (5-FU) in patients with HER2-negative and pMMR metastatic gastric cancer. Irinotecan will be administered as intravenous infusion of 150 mg/m2 every 2 weeks. Oxaliplatin will be given 85 mg/m2 and 5-FU will be given 400mg/m2 iv and 2400mg/m2 civ 48 hours fortnightly. Treatment will continue until disease progress or untolerable toxicity appears. The target sample size is 350-400 patients.


Clinical Trial Description

Eligible patients will be randomly assigned to FOLFOXiri group and FOLFOX group. Stratification factors include ECOG PS, disease extent and pathological subtypes. Efficacy will be evaluated every 3-4 cycles with RECIST. Toxicity will be assessed with WHO CTC 3.0 every 2 weeks. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04358354
Study type Interventional
Source Sixth Affiliated Hospital, Sun Yat-sen University
Contact Xiaohui Zhai, MD, PhD
Phone 86-20-38285497
Email zhaixh@mail.sysu.edu.cn
Status Recruiting
Phase Phase 3
Start date October 22, 2020
Completion date December 31, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT04618809 - Improving the Approach to and Management of the Older Patient With Metastatic Gastric Cancer N/A
Recruiting NCT02668380 - An Open Label, Prospective, Multicentre, Non-interventional Study of Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer N/A
Completed NCT03121807 - Home Parenteral Nutrition for Malnourished Unresectable Stage IV Gastric Cancer N/A
Completed NCT01099527 - A Trial of RAD001/Capecitabine in Refractory Gastric Cancer Phase 1/Phase 2
Completed NCT00253370 - Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer Phase 2
Recruiting NCT02002195 - Modified Folinic Acid-Fluorouracil-Oxaliplatin Regimen + Capecitabine for Elderly With Metastatic Gastric Cancer
Recruiting NCT06008925 - Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer Phase 1/Phase 2
Recruiting NCT05714124 - Liver Embolization Approaches for Tumor Management
Recruiting NCT02855788 - Metronomic Chemotherapy in Advanced Gastric Cancer Phase 2
Recruiting NCT03154983 - The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer Phase 2
Not yet recruiting NCT04263870 - Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction Phase 2
Active, not recruiting NCT01359397 - Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer Phase 2
Recruiting NCT04739202 - Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST) Phase 2
Completed NCT03409848 - Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma Phase 2
Recruiting NCT05859477 - Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer Phase 2
Recruiting NCT05955833 - 89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study Phase 1
Terminated NCT01528501 - Histone Deacetylases - Gastric Cancer (HDAC-GaCa-2008) Phase 2
Completed NCT03751761 - GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study Phase 1/Phase 2
Recruiting NCT05024812 - Fruquintinib Combined With Toripalimab and SOX Regimen in the First-line Treatment of Advanced Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Phase 1/Phase 2
Active, not recruiting NCT03614013 - Resistance to Immunotherapy in Gastric Cancer